Last 12 months
Inside the activity.
0 purchase rows · 35 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 16 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 17 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 1, 2026 21:48 UTC |
Coe Mary EllenDirector
|
GrantPhantom Stock · Derivative | 206.4552 | $145.31 | $30,000.01 |
DisclosureSEC source: 0000310158-26-000230 · form4.xml · derivative · entry 2 Coe Mary Ellen · CIK 0001691304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,419.8658 Underlying: Common Stock · 206.4552 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| September 30, 2026 Filed Oct 1, 2026 21:50 UTC |
Karsanbhai Surendralal LancaDirector
|
GrantPhantom Stock · Derivative | 111.8299 | $145.31 | $16,250.00 |
DisclosureSEC source: 0000310158-26-000232 · form4.xml · derivative · entry 2 Karsanbhai Surendralal Lanca · CIK 0001754881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,667.0117 Underlying: Common Stock · 111.8299 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| September 30, 2026 Filed Oct 1, 2026 21:52 UTC |
Seidman Christine EDirector
|
GrantPhantom Stock · Derivative | 55.9149 | $145.31 | $8,124.99 |
DisclosureSEC source: 0000310158-26-000234 · form4.xml · derivative · entry 2 Seidman Christine E · CIK 0001805745 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,490.4009 Underlying: Common Stock · 55.9149 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 13, 2026 Filed Aug 13, 2026 21:02 UTC |
Guindo ChirfiEVP, Access, Policy & Comms
|
SaleCommon Stock | 10,000 | $135.00 | $1,350,000.00 |
DisclosureSEC source: 0000310158-26-000223 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · EVP, Access, Policy & Comms 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,613.127 Read SEC document |
| August 12, 2026 Filed Aug 12, 2026 20:10 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Heallth
|
SaleCommon Stock | 600 | $132.04 | $79,222.02 |
DisclosureSEC source: 0000310158-26-000219 · form4.xml · nonDerivative · entry 5 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,167.07 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.0000 to $132.0700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 12, 2026 20:10 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Heallth
|
SaleCommon Stock | 11,099 | $131.61 | $1,460,770.47 |
DisclosureSEC source: 0000310158-26-000219 · form4.xml · nonDerivative · entry 4 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,767.07 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.9950, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 13, 2026 20:11 UTC |
Zachary JenniferEVP, General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 13,433 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0000310158-26-000221 · form4.xml · derivative · entry 5 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,433 shares Expires 2035-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options vest and become exercisable in equal installments on 4/29/2026, 4/29/2027, and 4/29/2028. Read SEC document |
| August 12, 2026 Filed Aug 13, 2026 20:11 UTC |
Zachary JenniferEVP, General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 41,494 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0000310158-26-000221 · form4.xml · derivative · entry 4 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,494 shares Expires 2033-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested and became exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| August 12, 2026 Filed Aug 13, 2026 20:11 UTC |
Zachary JenniferEVP, General Counsel
|
SaleCommon Stock | 80,315 | $133.46 | $10,718,494.55 |
DisclosureSEC source: 0000310158-26-000221 · form4.xml · nonDerivative · entry 3 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,509.254 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.0300 to $133.5000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 13, 2026 20:11 UTC |
Zachary JenniferEVP, General Counsel
|
Exercise / conversionCommon Stock | 13,433 | $84.71 | $1,137,909.43 |
DisclosureSEC source: 0000310158-26-000221 · form4.xml · nonDerivative · entry 2 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,824.254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2026 Filed Aug 13, 2026 20:11 UTC |
Zachary JenniferEVP, General Counsel
|
Exercise / conversionCommon Stock | 41,494 | $117.89 | $4,891,727.66 |
DisclosureSEC source: 0000310158-26-000221 · form4.xml · nonDerivative · entry 1 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,391.254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 20:10 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Heallth
|
SaleCommon Stock | 5,427 | $132.35 | $718,261.28 |
DisclosureSEC source: 0000310158-26-000219 · form4.xml · nonDerivative · entry 3 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,866.07 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.0000 to $132.6514, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 20:10 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Heallth
|
SaleCommon Stock | 7,410 | $131.33 | $973,164.93 |
DisclosureSEC source: 0000310158-26-000219 · form4.xml · nonDerivative · entry 2 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,293.07 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.9800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:10 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Heallth
|
SaleCommon Stock | 20,784 | $130.43 | $2,710,950.65 |
DisclosureSEC source: 0000310158-26-000219 · form4.xml · nonDerivative · entry 1 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,703.07 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.0000 to $130.9500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| August 06, 2026 Filed Aug 7, 2026 20:17 UTC |
Guindo ChirfiEVP, Access, Policy & Comms
|
SaleCommon Stock | 15,000 | $131.00 | $1,965,000.00 |
DisclosureSEC source: 0000310158-26-000213 · form4.xml · nonDerivative · entry 1 Guindo Chirfi · CIK 0001722753 · EVP, Access, Policy & Comms 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,613.127 Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:28 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Heallth
|
SaleCommon Stock | 300 | $131.02 | $39,306.99 |
DisclosureSEC source: 0000310158-26-000217 · form4.xml · nonDerivative · entry 3 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,487.07 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.0300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:28 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Heallth
|
SaleCommon Stock | 4,945 | $130.23 | $643,993.28 |
DisclosureSEC source: 0000310158-26-000217 · form4.xml · nonDerivative · entry 2 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,787.07 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.0000 to $130.9200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:28 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Heallth
|
SaleCommon Stock | 805 | $131.02 | $105,472.39 |
DisclosureSEC source: 0000310158-26-000217 · form4.xml · nonDerivative · entry 1 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,732.07 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.0000 to $131.0700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:19 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 34,705 | $0.00 Strike: $73.73 | $0.00 |
DisclosureSEC source: 0000310158-26-000214 · form4.xml · derivative · entry 9 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,705 shares Expires 2031-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F5 · derivative.exercise_date: The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:19 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 13,542 | $0.00 Strike: $75.36 | $0.00 |
DisclosureSEC source: 0000310158-26-000214 · form4.xml · derivative · entry 8 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,542 shares Expires 2030-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:19 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,600 | $0.00 Strike: $77.62 | $0.00 |
DisclosureSEC source: 0000310158-26-000214 · form4.xml · derivative · entry 7 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,600 shares Expires 2029-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested and became exercisable in three equal installments on 5/3/2020, 5/3/2021, and 5/3/2022. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:19 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
SaleCommon Stock | 34,705 | $128.77 | $4,468,987.14 |
DisclosureSEC source: 0000310158-26-000214 · form4.xml · nonDerivative · entry 6 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,716.037 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.7050 to $128.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:19 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
Exercise / conversionCommon Stock | 34,705 | $73.73 | $2,558,799.65 |
DisclosureSEC source: 0000310158-26-000214 · form4.xml · nonDerivative · entry 5 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,421.037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:19 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
SaleCommon Stock | 13,542 | $128.77 | $1,743,812.82 |
DisclosureSEC source: 0000310158-26-000214 · form4.xml · nonDerivative · entry 4 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,716.037 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.7050 to $128.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:19 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
Exercise / conversionCommon Stock | 13,542 | $75.36 | $1,020,525.12 |
DisclosureSEC source: 0000310158-26-000214 · form4.xml · nonDerivative · entry 3 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,258.037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:19 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
SaleCommon Stock | 4,600 | $128.77 | $592,345.22 |
DisclosureSEC source: 0000310158-26-000214 · form4.xml · nonDerivative · entry 2 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,716.037 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.7050 to $128.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:19 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
Exercise / conversionCommon Stock | 4,600 | $77.62 | $357,052.00 |
DisclosureSEC source: 0000310158-26-000214 · form4.xml · nonDerivative · entry 1 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,316.037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:21 UTC |
Maraldo David R.EVP & Pres. MMD
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,686 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0000310158-26-000215 · form4.xml · derivative · entry 9 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,374 Underlying: Common Stock · 2,686 shares Expires 2035-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vest and become exercisable in three equal installments on 4/29/2026, 4/29/2027, and 4/29/2028. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:21 UTC |
Maraldo David R.EVP & Pres. MMD
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 9,709 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0000310158-26-000215 · form4.xml · derivative · entry 8 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,709 shares Expires 2032-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and become exercisable in three equal installments on 5/3/2023, 5/3/2024, and 5/3/2025. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:21 UTC |
Maraldo David R.EVP & Pres. MMD
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,311 | $0.00 Strike: $73.73 | $0.00 |
DisclosureSEC source: 0000310158-26-000215 · form4.xml · derivative · entry 7 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,154 Underlying: Common Stock · 6,311 shares Expires 2031-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested and became exercisable in three equal installments on 5/4/2022, 5/4/2023, and 5/4/2024. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:21 UTC |
Maraldo David R.EVP & Pres. MMD
|
SaleCommon Stock | 2,686 | $128.72 | $345,736.28 |
DisclosureSEC source: 0000310158-26-000215 · form4.xml · nonDerivative · entry 6 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,212.434 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.6400 to $128.8500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in the footnote. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:21 UTC |
Maraldo David R.EVP & Pres. MMD
|
Exercise / conversionCommon Stock | 2,686 | $84.71 | $227,531.06 |
DisclosureSEC source: 0000310158-26-000215 · form4.xml · nonDerivative · entry 5 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,898.434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:21 UTC |
Maraldo David R.EVP & Pres. MMD
|
SaleCommon Stock | 9,709 | $128.72 | $1,249,722.09 |
DisclosureSEC source: 0000310158-26-000215 · form4.xml · nonDerivative · entry 4 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,212.434 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.6400 to $128.8500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in the footnote. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:21 UTC |
Maraldo David R.EVP & Pres. MMD
|
Exercise / conversionCommon Stock | 9,709 | $87.10 | $845,653.90 |
DisclosureSEC source: 0000310158-26-000215 · form4.xml · nonDerivative · entry 3 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,921.434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:21 UTC |
Maraldo David R.EVP & Pres. MMD
|
SaleCommon Stock | 6,311 | $128.72 | $812,338.67 |
DisclosureSEC source: 0000310158-26-000215 · form4.xml · nonDerivative · entry 2 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,212.434 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.6400 to $128.8500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in the footnote. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:21 UTC |
Maraldo David R.EVP & Pres. MMD
|
Exercise / conversionCommon Stock | 6,311 | $73.73 | $465,310.03 |
DisclosureSEC source: 0000310158-26-000215 · form4.xml · nonDerivative · entry 1 Maraldo David R. · CIK 0002126478 · EVP & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,523.434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 12:41 UTC |
Coe Mary EllenDirector
|
GrantPhantom Stock · Derivative | 233.463 | $128.50 | $30,000.00 |
DisclosureSEC source: 0000310158-26-000198 · form4.xml · derivative · entry 2 Coe Mary Ellen · CIK 0001691304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,999.1016 Underlying: Common Stock · 233.463 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 12:44 UTC |
Karsanbhai Surendralal LancaDirector
|
GrantPhantom Stock · Derivative | 126.4591 | $128.50 | $16,249.99 |
DisclosureSEC source: 0000310158-26-000200 · form4.xml · derivative · entry 2 Karsanbhai Surendralal Lanca · CIK 0001754881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,518.8018 Underlying: Common Stock · 126.4591 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 12:47 UTC |
Seidman Christine EDirector
|
GrantPhantom Stock · Derivative | 63.2296 | $128.50 | $8,125.00 |
DisclosureSEC source: 0000310158-26-000202 · form4.xml · derivative · entry 2 Seidman Christine E · CIK 0001805745 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,291.269 Underlying: Common Stock · 63.2296 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 17:57 UTC |
BAKER DOUGLAS M JRDirector
|
GrantPhantom Stock · Derivative | 1,853.0997 | $118.72 | $220,000.00 |
DisclosureSEC source: 0000310158-26-000146 · form4.xml · derivative · entry 2 BAKER DOUGLAS M JR · CIK 0001198753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,518.2084 Underlying: Common Stock · 1,853.0997 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 18:03 UTC |
Craig Pamela J.Director
|
GrantPhantom Stock · Derivative | 1,853.0997 | $118.72 | $220,000.00 |
DisclosureSEC source: 0000310158-26-000148 · form4.xml · derivative · entry 2 Craig Pamela J. · CIK 0001232910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,944.9297 Underlying: Common Stock · 1,853.0997 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 18:05 UTC |
GLOCER THOMAS HDirector
|
GrantPhantom Stock · Derivative | 1,853.0997 | $118.72 | $220,000.00 |
DisclosureSEC source: 0000310158-26-000150 · form4.xml · derivative · entry 2 GLOCER THOMAS H · CIK 0001140799 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,911.7587 Underlying: Common Stock · 1,853.0997 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 18:11 UTC |
Mayo StephenDirector
|
GrantPhantom Stock · Derivative | 1,853.0997 | $118.72 | $220,000.00 |
DisclosureSEC source: 0000310158-26-000155 · form4.xml · derivative · entry 2 Mayo Stephen · CIK 0001849061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,824.5202 Underlying: Common Stock · 1,853.0997 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 18:09 UTC |
LAVIZZO-MOUREY RISA JDirector
|
GrantPhantom Stock · Derivative | 1,853.0997 | $118.72 | $220,000.00 |
DisclosureSEC source: 0000310158-26-000153 · form4.xml · derivative · entry 2 LAVIZZO-MOUREY RISA J · CIK 0001034465 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,749.3517 Underlying: Common Stock · 1,853.0997 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 18:14 UTC |
Rothman PaulDirector
|
GrantPhantom Stock · Derivative | 1,853.0997 | $118.72 | $220,000.00 |
DisclosureSEC source: 0000310158-26-000157 · form4.xml · derivative · entry 2 Rothman Paul · CIK 0001601332 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,944.9417 Underlying: Common Stock · 1,853.0997 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 18:17 UTC |
RUSSO PATRICIA FDirector
|
GrantPhantom Stock · Derivative | 1,853.0997 | $118.72 | $220,000.00 |
DisclosureSEC source: 0000310158-26-000159 · form4.xml · derivative · entry 2 RUSSO PATRICIA F · CIK 0001023219 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,390.7517 Underlying: Common Stock · 1,853.0997 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 18:19 UTC |
Seidman Christine EDirector
|
GrantPhantom Stock · Derivative | 1,853.0997 | $118.72 | $220,000.00 |
DisclosureSEC source: 0000310158-26-000161 · form4.xml · derivative · entry 2 Seidman Christine E · CIK 0001805745 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,228.0394 Underlying: Common Stock · 1,853.0997 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 18:21 UTC |
THULIN INGE GDirector
|
GrantPhantom Stock · Derivative | 1,853.0997 | $118.72 | $220,000.00 |
DisclosureSEC source: 0000310158-26-000163 · form4.xml · derivative · entry 2 THULIN INGE G · CIK 0001263739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,469.7107 Underlying: Common Stock · 1,853.0997 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 18:26 UTC |
Coe Mary EllenDirector
|
GrantPhantom Stock · Derivative | 1,853.0997 | $118.72 | $220,000.00 |
DisclosureSEC source: 0000310158-26-000166 · form4.xml · derivative · entry 2 Coe Mary Ellen · CIK 0001691304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,765.6386 Underlying: Common Stock · 1,853.0997 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 19:31 UTC |
Karsanbhai Surendralal LancaDirector
|
GrantPhantom Stock · Derivative | 1,853.0997 | $118.72 | $220,000.00 |
DisclosureSEC source: 0000310158-26-000171 · form4.xml · derivative · entry 2 Karsanbhai Surendralal Lanca · CIK 0001754881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,392.3427 Underlying: Common Stock · 1,853.0997 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.